Setback
Johnson & Johnson pushed back the first human trials of Ottava by two years, to the second half of 2024, citing COVID-19 and supply problems.
A delay, pause or setback · Company-reported
What the source says
“which will now be pushed back to the second half of 2024.”
What it means
Ottava, from Johnson & Johnson, is at stage 5 of 5 on our ladder: regulator-cleared or mass market. A setback stays on the record next to the milestones; the stage moves down only when the rules say so. This line rests on the company's own announcement; no regulator, customer or independent report confirms it in our sources yet.
Human help: The maker hasn't said whether people help it remotely.
More on Ottava
- A separate US clinical trial of Ottava for groin (inguinal) hernia repair was still going on.
- The FDA granted Ottava De Novo authorization for 10 general surgery operations in the upper belly, including gastric bypass, gallbladder removal and hiatal hernia repair.
- Surgeons did the first operations with Ottava, gastric bypass surgeries, as part of the US clinical trial.
- The FDA allowed Johnson & Johnson to start a US clinical trial of Ottava (an investigational device exemption).
- Johnson & Johnson gave the first public look at Ottava.